PAGE 1

PRODUCT

INFORMATION

1 2 F XXXXXXXX 3

- 4
- 5
- 6
- 7 TEMODAR[®]

8 (temozolomide)

9 CAPSULES

10

11 DESCRIPTION

12 TEMODAR Capsules for oral administration contain temozolomide, an 13 imidazotetrazine derivative. The chemical name of temozolomide is 3,4-dihydro-3-

14 methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide. The structural formula is:



15

16

17 The material is a white to light tan/light pink powder with a molecular formula of 18 $C_6H_6N_6O_2$ and a molecular weight of 194.15. The molecule is stable at acidic pH 19 (<5), and labile at pH >7, hence TEMODAR can be administered orally. The 20 prodrug, temozolomide, is rapidly hydrolysed to the active 5-(3-methyltriazen-1-yl) 21 imidazole-4-carboxamide (MTIC) at neutral and alkaline pH values, with hydrolysis 22 taking place even faster at alkaline pH.

Each capsule contains either 5 mg, 20 mg, 100 mg, or 250 mg of temozolomide. The inactive ingredients for TEMODAR Capsules are lactose anhydrous, colloidal silicon dioxide, sodium starch glycolate, tartaric acid, and stearic acid. Gelatin capsule shells contain titanium dioxide. The capsules are white and imprinted with pharmaceutical ink.

TEMODAR 5 mg: green imprint contains pharmaceutical grade shellac, anhydrous
 ethyl alcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, ammonium
 hydroxide, titanium dioxide, yellow iron oxide, and FD&C Blue #2 aluminum lake.

TEMODAR 20 mg: brown imprint contains pharmaceutical grade shellac, anhydrous
 ethyl alcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, purified water,
 ammonium hydroxide, potassium hydroxide, titanium dioxide, black iron oxide,
 yellow iron oxide, brown iron oxide, and red iron oxide.

35 *TEMODAR 100 mg:* blue imprint contains pharmaceutical glaze (modified) in an

ethanol/shellac mixture, isopropyl alcohol, n-butyl alcohol, propylene glycol, titanium
 dioxide, and FD & C Blue #2 aluminum lake.



TEMODAR 250 mg: black, imprint contains pharmaceutical grade shellac,
 anhydrous ethyl alcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, purified
 water, ammonium hydroxide, potassium hydroxide, and black iron oxide.

41

42 CLINICAL PHARMACOLOGY

43 Mechanism of Action: Temozolomide is not directly active but undergoes rapid
 44 nonenzymatic conversion at physiologic pH to the reactive compound MTIC. The
 45 cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA. Alkylation
 46 (methylation) occurs mainly at the O⁶ and N⁷ positions of guanine.

47

48 **Pharmacokinetics:** Temozolomide is rapidly and completely absorbed after oral 49 administration; peak plasma concentrations occur in 1 hour. Food reduces the rate 50 and extent of temozolomide absorption. Mean peak plasma concentration and AUC 51 decreased by 32% and 9%, respectively, and T_{max} increased 2-fold (from 1.1 to 2.25) 52 hours) when temozolomide was administered after a modified high-fat breakfast. 53 temozolomide is rapidly eliminated with a mean elimination half-life of 1.8 hours and 54 exhibits linear kinetics over the therapeutic dosing range. Temozolomide has a 55 mean apparent volume of distribution of 0.4 L/kg (%CV=13%). It is weakly bound to 56 human plasma proteins; the mean percent bound of drug-related total radioactivity is 57 15%.

58

59 Metabolism and Elimination: Temozolomide is spontaneously hydrolyzed at 60 physiologic pH to the active species, 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) and to temozolomide acid metabolite. MTIC is further hvdrolvzed 61 62 to 5-amino-imidazole-4-carboxamide (AIC) which is known to be an intermediate in 63 purine and nucleic acid biosynthesis and to methylhydrazine, which is believed to be 64 the active alkylating species. Cytochrome P450 enzymes play only a minor role in 65 the metabolism of temozolomide and MTIC. Relative to the AUC of temozolomide. 66 the exposure to MTIC and AIC is 2.4% and 23%, respectively. About 38% of the 67 administered temozolomide total radioactive dose is recovered over 7 days; 37.7% 68 in urine and 0.8% in feces. The majority of the recovery of radioactivity in urine is as 69 unchanged temozolomide (5.6%), AIC (12%), temozolomide acid metabolite (2.3%), 70 and unidentified polar metabolite(s) (17%). Overall clearance of temozolomide is 71 about 5.5 L/hr/m².

72

Special Populations: Age Population pharmacokinetic analysis indicates that age
 (range 19 to 78 years) has no influence on the pharmacokinetics of temozolomide.
 In the anaplastic astrocytoma study population, patients 70 years of age or older had
 a higher incidence of Grade 4 neutropenia and Grade 4 thrombocytopenia in the first
 cycle of therapy than patients under 70 years of age (see PRECAUTIONS).

78

Gender Population pharmacokinetic analysis indicates that women have an
 approximately 5% lower clearance (adjusted for body surface area) for
 temozolomide than men. Women have higher incidences of Grade 4 neutropenia
 and thrombocytopenia in the first cycle of therapy than men (see ADVERSE
 REACTIONS).



85 *Race* The effect of race on the pharmacokinetics of temozolomide has not been 86 studied.

87

Tobacco Use Population pharmacokinetic analysis indicates that the oral clearance
 of temozolomide is similar in smokers and nonsmokers.

90

91 *Creatinine Clearance* Population pharmacokinetic analysis indicates that creatinine 92 clearance over the range of 36-130 mL/min/m² has no effect on the clearance of 93 temozolomide after oral administration. The pharmacokinetics of temozolomide have 94 not been studied in patients with severely impaired renal function (CLcr <36 95 mL/min/m²). Caution should be exercised when TEMODAR Capsules are 96 administered to patients with severe renal impairment. TEMODAR has not been 97 studied in patients on dialysis.

98

Hepatically Impaired Patients In a pharmacokinetic study, the pharmacokinetics of
 temozolomide in patients with mild-to-moderate hepatic impairment (Child's-Pugh
 Class I - II) were similar to those observed in patients with normal hepatic function.
 Caution should be exercised when temozolomide is administered to patients with
 severe hepatic impairment.

104

105 *Drug-Drug Interactions* In a multiple-dose study, administration of TEMODAR 106 Capsules with ranitidine did not change the C_{max} or AUC values for temozolomide or 107 MTIC. Population analysis indicates that administration of valproic acid decreases 108 the clearance of temozolomide by about 5% (see **PRECAUTIONS**).

Population analysis failed to demonstrate any influence of coadministered dexamethasone, prochlorperazine, phenytoin, carbamazepine, ondansetron, H₂receptor antagonists, or phenobarbital on the clearance of orally administered temozolomide.

113


114 CLINICAL STUDIES

115 Newly Diagnosed Glioblastoma Multiforme Five hundred and seventy-116 three patients were randomized to receive either TEMODAR (TMZ) + Radiotherapy 117 (RT) (n= 287) or RT alone (n=286). Patients in the TEMODAR + RT arm received concomitant TEMODAR (75 mg/m²) once daily, starting the first day of RT until the 118 119 last day of RT, for 42 days (with a maximum of 49 days). This was followed by 6 cycles of Temodar alone (150 or 200 mg/m²) on day 1 -5 of every 28-day cycle, 120 121 starting 4 weeks after the end of RT. Patients in the control arm received RT only. In 122 both arms focal radiation therapy was delivered as 60 Gy/30 fractions. Focal RT 123 includes the tumor bed or resection site with a 2-3 cm margin. Pneumocystis carinii 124 pneumonia (PCP) prophylaxis was required during the TMZ + radiotherapy 125 treatment, regardless of lymphocyte count, and was to continue until recovery of 126 lymphocyte count to less than or equal to grade 1.



128 At the time of disease progression, TEMODAR was administered as salvage therapy

- in 161 patients of the 282 (57 %) in the RT alone arm, and 62 patients of the 277 (22%) in the TEMODAR + RT arm.
- 131 The addition of concomitant and maintenance TEMODAR to radiotherapy in the
- 132 treatment of patients with newly diagnosed GBM showed a statistically significant
- 133 improvement overall survival compared radiotherapy alone. (Figure 1) The hazard
- ratio (HR) for overall survival was 0.63 (95 % CI for HR=0.52-0.75) with a log-rank p
- 135 <0.0001 in favor of the TEMODAR arm. The median survival was increased by 2 $\frac{1}{2}$
- 136 months in the TEMODAR arm.
- 137



138

139

Figure 1 Kaplan-Meier Curves for Overall Survival (ITT Population)

140

141 Refractory (Anaplastic Astrocytoma)

142 A single-arm, multicenter study was conducted in 162 patients who had anaplastic 143 astrocytoma at first relapse and who had a baseline Karnofsky performance status 144 of 70 or greater. Patients had previously received radiation therapy and may also 145 have previously received a nitrosourea with or without other chemotherapy. Fifty-four 146 patients had disease progression on prior therapy with both a nitrosourea and 147 procarbazine and their malignancy was considered refractory to chemotherapy 148 (refractory anaplastic astrocytoma population). Median age of this subgroup of 54 149 patients was 42 years (19 to 76). Sixty-five percent were male. Seventy-two percent 150 of patients had a KPS of >80. Sixty-three percent of patients had surgery other than 151 a biopsy at the time of initial diagnosis. Of those patients undergoing resection, 73%



underwent a subtotal resection and 27% underwent a gross total resection. Eighteen
percent of patients had surgery at the time of first relapse. The median time from
initial diagnosis to first relapse was 13.8 months (4.2 to 75.4).

155 TEMODAR Capsules were given for the first 5 consecutive days of a 28-day cycle at 156 a starting dose of 150 mg/m²/day. If the nadir and day of dosing (Day 29, Day 1 of 157 next cycle) absolute neutrophil count was >1.5 x 10^{9} /L (1,500/µL) and the nadir and 158 Day 29, Day 1 of next cycle, platelet count was >100 x 10^{9} /L (100,000/µL), the 159 TEMODAR dose was increased to 200 mg/m²/day for the first 5 consecutive days of 160 a 28-day cycle.

161 In the refractory anaplastic astrocytoma population the overall tumor response rate 162 (CR + PR) was 22% (12/54 patients) and the complete response rate was 9% (5/54 163 patients). The median duration of all responses was 50 weeks (range of 16 to 114 164 weeks) and the median duration of complete responses was 64 weeks (range of 52 165 to 114 weeks). In this population, progression-free survival at 6 months was 45% 166 (95% confidence interval 31% to 58%) and progression-free survival at 12 months 167 was 29% (95% confidence interval 16% to 42%). Median progression-free survival 168 was 4.4 months. Overall survival at 6 months was 74% (95% confidence interval 169 62% to 86%) and 12-month overall survival was 65% (95% confidence interval 52% 170 to 78%). Median overall survival was 15.9 months. 171

172 INDICATIONS AND USAGE

173 TEMODAR (temozolomide) Capsules are indicated for the treatment of adult 174 patients with newly diagnosed glioblastoma multiforme concomitantly with 175 radiotherapy and then as maintenance treatment.

176

177 TEMODAR Capsules are indicated for the treatment of adult patients with refractory
178 anaplastic astrocytoma, i.e. patients who have experienced disease progression on
179 a drug regimen containing nitrosurea and procarbazine.

180

181 **CONTRAINDICATIONS**

TEMODAR (temozolomide) Capsules are contraindicated in patients who have a
history of hypersensitivity reaction to any of its components. TEMODAR is also
contraindicated in patients who have a history of hypersensitivity to DTIC, since both
drugs are metabolized to MTIC.

186

187 WARNINGS

188 Patients treated with TEMODAR Capsules may experience myelosuppression. Prior 189 to dosing, patients must have an absolute neutrophil count (ANC) >1.5 x 10^{9} /L and a 190 platelet count >100 x 10⁹/L. A complete blood count should be obtained on Day 22 191 (21 days after the first dose) or within 48 hours of that day, and weekly until the ANC 192 is above 1.5 x 10⁹/L and platelet count exceeds 100 x10⁹/L.Geriatric patients and 193 women have been shown in clinical trials to have a higher risk of developing 194 myelosuppression. Very rare cases of myelodysplastic syndrome and secondary 195 malignancies, including myeloid leukemia have also been observed.



For treatment of newly diagnosed glioblastoma multiforme: Prophylaxis against
 Pneumocystis carinii pneumonia is required for all patients receiving concomitant
 TEMODAR and radiotherapy for the 42 day regimen.

There may be a higher occurrence of PCP when temozolomide is administered during a longer dosing regimen. However, all patients receiving temozolomide, particularly patients receiving steroids should be observed closely for the development of PCP regardless of the regimen.

204

205 **Pregnancy:** Temozolomide may cause fetal harm when administered to a pregnant 206 woman. Five consecutive days of oral administration of 75 mg/m²/day in rats and 207 150 mg/m²/day in rabbits during the period of organogenesis (3/8 and 3/4 the 208 maximum recommended human dose. respectively) caused numerous 209 malformations of the external organs, soft tissues, and skeleton in both species. 210 Doses of 150 mg/m²/day in rats and rabbits also caused embryolethality as indicated 211 by increased resorptions. There are no adequate and well-controlled studies in 212 pregnant women. If this drug is used during pregnancy, or if the patient becomes 213 pregnant while taking this drug, the patient should be apprised of the potential 214 hazard to the fetus. Women of childbearing potential should be advised to avoid 215 becoming pregnant during therapy with TEMODAR Capsules.

216

217 **PRECAUTIONS**

Information for Patients: Nausea and vomiting were among the most frequently occurring adverse events. These were usually either self-limiting or readily controlled with standard antiemetic therapy. Capsules should not be opened. If capsules are accidentally opened or damaged, rigorous precautions should be taken with the capsule contents to avoid inhalation or contact with the skin or mucous membranes. The medication should be kept away from children and pets.

224

Drug Interaction: Administration of valproic acid decreases oral clearance of
 temozolomide by about 5%. The clinical implication of this effect is not known.

227

Patients with Severe Hepatic or Renal Impairment: Caution should be exercised
 when TEMODAR Capsules are administered to patients with severe hepatic or renal
 impairment (see Special Populations).

231

Geriatrics: Clinical studies of temozolomide did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Caution should be exercised when treating elderly patients.

In the anaplastic astrocytoma study population, patients 70 years of age or older had
a higher incidence of Grade 4 neutropenia and Grade 4 thrombocytopenia (2/8;
25%, p=.31 and 2/10; 20%, p=.09, respectively) in the first cycle of therapy than
patients under 70 years of age (see ADVERSE REACTIONS).

In newly diagnosed patients with glioblastoma multiforme the adverse event profile
 was similar in younger patients (<65 years) vs older (≥65 years).



Laboratory Tests: For the concomitant treatment phase with RT a complete blood count should be obtained weekly.

For the 28 day treatment cycles, a complete blood count should be obtained on Day 247 22 (21 days after the first dose). Blood counts should be performed weekly until 248 recovery if the ANC falls below 1.5×10^{9} /L and the platelet count falls below 100 x 249 10^{9} /L.

250

251 Fertility: Mutagenesis, and Impairment of Carcinogenesis. Standard 252 carcinogenicity studies were not conducted with temozolomide. In rats treated with 200 mg/m² temozolomide (equivalent to the maximum recommended daily human 253 254 dose) on 5 consecutive days every 28 days for 3 cycles, mammary carcinomas were 255 found in both males and females. With 6 cycles of treatment at 25, 50, and 125 256 mg/m² (about 1/8 to 1/2 the maximum recommended daily human dose), mammary carcinomas were observed at all doses and fibrosarcomas of the heart, eve, seminal 257 258 vesicles, salivary glands, abdominal cavity, uterus, and prostate; carcinoma of the 259 seminal vesicles, schwannoma of the heart, optic nerve, and harderian gland; and 260 adenomas of the skin, lung, pituitary, and thyroid were observed at the high dose.

Temozolomide was mutagenic *in vitro* in bacteria (Ames assay) and clastogenic in mammalian cells (human peripheral blood lymphocyte assays).

Reproductive function studies have not been conducted with temozolomide. However, multicycle toxicology studies in rats and dogs have demonstrated testicular toxicity (syncytial cells/immature sperm, testicular atrophy) at doses of 50 mg/m² in rats and 125 mg/m² in dogs (1/4 and 5/8, respectively, of the maximum recommended human dose on a body surface area basis).

268

269 **Pregnancy Category D:** See **WARNINGS** section.

270

Nursing Mothers: It is not known whether this drug is excreted in human milk.
 Because many drugs are excreted in human milk and because of the potential for
 serious adverse reactions in nursing infants from TEMODAR Capsules, patients
 receiving TEMODAR should discontinue nursing.

275

276 **Pediatric Use:**

277 TEMODAR effectiveness in children has not been demonstrated. TEMODAR 278 Capsules have been studied in 2 open label Phase 2 studies in pediatric patients (age 3-18 years) at a dose of 160-200 mg/m² daily for 5 days every 28 days. In one 279 280 trial conducted by the Schering Corporation, 29 patients with recurrent brain stem 281 glioma and 34 patients with recurrent high grade astrocytoma were enrolled. All patients had failed surgery and radiation therapy, while 31% also failed 282 283 chemotherapy. In a second Phase 2 open label study conducted by the Children's 284 Oncoloav Group (COG). 122 patients were enrolled. including 285 medulloblastoma/PNET(29), high grade astrocytoma (23), low grade astrocytoma 286 (22), brain stem glioma (16), ependymoma (14) other CNS tumors (9) and non-CNS 287 tumors (9). The TEMODAR toxicity profile in children is similar to adults. Table 1 288 shows the adverse events in 122 children in the COG Phase 2 study.



Table 1

Adverse Events Reported in Pediatric Co	Cooperative Group Trial (≥10%) No. (%) of TEMODAR			
	Patients (I			
Body System/Organ Class Adverse Event	All Events	Gr 3/4		
Subjects Reporting an AE Body as a Whole	107 (88)	69 (57)		
Central and Peripheral Nervous System				
Central cerebral CNS cortex	22 (18)	13 (11)		
Gastrointestinal System				
Nausea	56 (46)	5 (4)		
Vomiting	62 (51)	4 (3)		
Platelet, Bleeding and Clotting				
Thrombocytopenia	71 (58)	31 (25)		
Red Blood Cell Disorders				
Decreased Hemoglobin	62 (51)	7 (6)		
White Cell and RES Disorders				
Decreased WBC	71 (58)	21 (17)		
Lymphopenia	73 (60)	48 (39)		
Neutropenia	62 (51)	24 (20)		

a: These various tumors included the following: PNET-medulloblastoma, glioblastoma, low grade astrocytoma, brain stem tumor, ependymoma, mixed glioma, oligodendroglioma, neuroblastoma, Ewings sarcoma, pineoblastoma, alveolar soft part sarcoma, neurofibrosarcoma, optic glioma, and osteosarcoma.

292 ADVERSE REACTIONS IN ADULTS

293 Newly Diagnosed Glioblastoma Multiforme

294

295 During the concomitant phase (Temodar + radiotherapy), adverse events including 296 thrombocytopenia, nausea, vomiting, anorexia and constipation, were more frequent 297 in the TEMODAR + RT arm the RT arm. The incidence of other adverse events 298 was comparable in the two arms. The most common adverse events across the 299 cumulative TEMODAR experience were alopecia, nausea, vomiting, anorexia, 300 headache, and constipation (see Table 2). Forty-nine percent (49%) of patients 301 treated with TEMODAR reported one or more severe or life-threatening events, most commonly fatigue (13%), convulsions (6%), headache (5%) and thrombocytopenia 302 303 (5%). Overall, the pattern of events during the maintenance phase was consistent 304 with the known safety profile of TEMODAR.



306Table 2Number (%) of Patients with Adverse Events: All and Severe/Life307Threatening (Incidence of 5% or Greater)

	Cor	RT A	ant Ph Alone 285)	ase	Cor	RT+	ant Ph TMZ 288)*	ase	Mai	Т	nce Ph MZ 224)	ase
	А	JI	Grad	e ≥ 3	А	dl 🛛	Grad	e ≥ 3	А	dl 🛛	Grad	e ≥ 3
Subjects Reporting any Adverse Event	258	(91)	74	(26)	266	(92)	80	(28)	206	(92)	82	(37)
Body as a Whole - General Disorders												
Anorexia	25	(9)	1	(<1)		(19)	2	(1)	61	(27)	3	(1)
Dizziness	10	(4)	0		12	(4)		(1)		(5)	0	
Fatigue	139	(49)		(5)	156	(54)	19	(7)	137	(61)	20	(9)
Headache	49	(17)	11	(4)	56	(19)	5	(2)	51	(23)	9	(4)
Weakness	9	(3)	3	(1)	10	(3)	5	(2)	16	(7)	4	(2)
Central and Peripheral Nervous System Disorders												
Confusion	12	(4)	6	(2)	11	(4)	4	(1)	12	(5)	4	(2)
Convulsions		(7)		(3)	17			(3)		(11)		(2)
Memory Impairment		(4)		(<1)	8	. ,		(<1)		(7)		(1)
Disorders of the Eye	12	(')		(• • •)	Ŭ	(0)		()	10	(')	-	(')
Vision Blurred	25	(9)	4	(1)	26	(9)	2	(1)	17	(8)	0	
Disorders of the Immune System	20	(0)	-	(')	20	(0)	2	(')	17	(0)	Ū	
Allergic Reaction	7	(2)	1	(<1)	13	(5)	0		6	(3)	0	
Gastro-Intestinal System	•	(-)		(.)		(0)			•	(0)	Ū	
Disorders												
Abdominal Pain	2	(1)	0		7	(2)	1	(<1)	11	(5)	1	(<1)
Constipation	18	(6)	0		53	(18)	3	(1)	49	(22)	0	
Diarrhea	9	(3)	0		18	(6)	0		23	(10)	2	(1)
Nausea	45	(16)	1	(<1)	105	(36)	2	(1)	110	(49)	3	(1)
Stomatitis	14	(5)	1	(<1)	19	(7)	0		20	(9)	3	(1)
Vomiting	16	(6)	1	(<1)	57	(20)	1	(<1)	66	(29)	4	(2)
Injury and Poisoning												
Radiation Injury NOS	11	(4)	1	(<1)	20	(7)	0		5	(2)	0	
Musculo-Skeletal System Disorders		-		·								
Arthralgia	2	(1)	0		7	(2)	1	(<1)	14	(6)	0	
Platelet, Bleeding and Clotting Disorders												
Thrombocytopenia	3	(1)	0		11	(4)	8	(3)	19	(8)	8	(4)
Psychiatric Disorders												
Insomnia	9	(3)	1	(<1)	14	(5)	0		9	(4)	0	
Respiratory System Disorders												
Coughing	3	(1)	0		15	(5)	2	(1)	19	(8)	1	(<1)
Dyspnea	9	(3)	4	(1)	11	(4)	5	(2)	12	(5)	1	(<1)



	Concomitant Phase RT Alone (n=285)		RT+	ant Phase TMZ 288)*	Maintenance Phase TMZ (n=224)	
	All	Grade ≥ 3	All	All Grade ≥ 3		Grade ≥ 3
Skin and Subcutaneous Tissue Disorders						
Alopecia	179 (63)	0	199 (69)	0	124 (55)	0
Dry Skin	6 (2)	0	7 (2)	0	11 (5)	1 (<1)
Erythema	15 (5)	0	14 (5)	0	2 (1)	0
Pruritus	4 (1)	0	11 (4)	0	11 (5)	0
Rash	42 (15)	0	56 (19)	3 (1)	29 (13)	3 (1)
Special Senses Other, Disorders						
Taste Perversion	6 (2)	0	18 (6)	0	11 (5)	0

312

313

*One patient who was randomized to RT only arm received RT + Temozolomide RT+TMZ=radiotherapy plus temozolomide; LT=life threatening; SGPT = serum glutamic pyruvic transaminase (=alanine aminotransferase [ALT]); NOS=not otherwise specified.

Note: Grade 5 (fatal) adverse events are included in the Grade \geq 3 column.

Myelosuppression, (neutropenia and thrombocytopenia), which are known dose limiting toxicities for most cytotoxic agents, including TEMODAR, were observed. When laboratory abnormalities and adverse events were combined, Grade 3 or Grade 4 neutrophil abnormalities including neutropenic events were observed in 8% of the patients and Grade 3 or Grade 4 platelet abnormalities, including thrombocytopenic events were observed in 14% of the patients treated with TEMODAR.

321

322 **Refractory anaplastic astrocytoma**

323 **Tables 3** and **4** show the incidence of adverse events in the 158 patients in the 324 anaplastic astrocytoma study for whom data are available. In the absence of a 325 control group, it is not clear in many cases whether these events should be attributed to temozolomide or the patients' underlying conditions, but nausea, 326 327 vomiting, fatigue, and hematologic effects appear to be clearly drug related. The 328 most frequently occurring side effects were nausea, vomiting, headache, and 329 fatigue. The adverse events were usually NCI Common Toxicity Criteria (CTC) 330 Grade 1 or 2 (mild to moderate in severity) and were self-limiting, with nausea and 331 vomiting readily controlled with antiemetics. The incidence of severe nausea and 332 vomiting (CTC Grade 3 or 4) was 10% and 6%, respectively. Myelosuppression 333 (thrombocytopenia and neutropenia) was the dose-limiting adverse event. It usually 334 occurred within the first few cycles of therapy and was not cumulative.

Myelosuppression occurred late in the treatment cycle and returned to normal, on average, within 14 days of nadir counts. The median nadirs occurred at 26 days for platelets (range 21 to 40 days) and 28 days for neutrophils (range 1 to 44 days). Only 14% (22/158) of patients had a neutrophil nadir and 20% (32/158) of patients had a platelet nadir which may have delayed the start of the next cycle. Less than 10% of patients required hospitalization, blood transfusion, or discontinuation of therapy due to myelosuppression.



In clinical trial experience with 110 to 111 women and 169 to 174 men (depending on measurements), there were higher rates of Grade 4 neutropenia (ANC < 500 cells/ μ L) and thrombocytopenia (< 20,000 cells/ μ L) in women than men in the first cycle of therapy: (12% versus 5% and 9% versus 3%, respectively).

In the entire safety database for which hematologic data exist (N=932), 7% (4/61) and 9.5% (6/63) of patients over age 70 experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively. For patients less than or equal to age 70, 7% (62/871) and 5.5% (48/879) experienced Grade 4 neutropenia or thrombocytopenia in the first cycle, respectively. Pancytopenia, leukopenia, and anemia have also been reported.

352

	Table 3		
Adverse Events in the A	naplastic Astrocytoma Trial i		
	No. (%) of TEMODA	1 <i>i</i>	
	All Events	Grade 3/4	
Any Adverse Event	153 (97)	79 (50)	
Body as a Whole			
Headache	65 (41)	10 (6)	
Fatigue	54 (34)	7 (4)	
Asthenia	20 (13)	9 (6)	
Fever	21 (13)	3 (2)	
Back pain	12 (8)	4 (3)	
Cardiovascular			
Edema peripheral	17 (11)	1 (1)	
Central and Peripheral Nervous			
System			
Convulsions	36 (23)	8 (5)	
Hemiparesis	29 (18)	10 (6)	
Dizziness	19 (12)	1 (1)	
Coordination abnormal	17 (11)	2 (1)	
Amnesia	16 (10)	6 (4)	
Insomnia	16 (10)	0	
Paresthesia	15 (9)	1 (1)	
Somnolence	15 (9)	5 (3)	
Paresis	13 (8)	4 (3)	
Urinary incontinence	13 (8)	3 (2)	
Ataxia	12 (8)	3 (2)	
Dysphasia	11 (7)	1 (1)	
Convulsions local	9 (6)	0	
Gait abnormal	9 (6)	1 (1)	
Confusion	8 (5)	0	
Endocrine			
Adrenal hypercorticism	13 (8)	0	
Gastrointestinal System			
Nausea	84 (53)	16 (10)	
Vomiting	66 (42)	10 (6)	
Constipation	52 (33)	1 (1)	
Diarrhea	25 (16)	3 (2)	
Abdominal pain	14 (9)	2 (1)	
Anorexia	14 (9)	1 (1)	
Metabolic			
Weight increase	8 (5)	0	



Musculoskeletal System		
Myalgia	8 (5)	
Psychiatric Disorders		
Anxiety	11 (7)	1 (1)
Depression	10 (6)	0
Reproductive Disorders		
Breast pain, female	4 (6)	
Resistance Mechanism		
Disorders		
Infection viral	17 (11)	0
Respiratory System		
Upper respiratory tract infection	13 (8)	0
Pharyngitis	12 (8)	0
Sinusitis	10 (6)	0
Coughing	8 (5)	0
Skin and Appendages		
Rash	13 (8)	0
Pruritus	12 (8)	2 (1)
Urinary System		
Urinary tract infection	12 (8)	0
Micturition increased frequency	9 (6)	0
Vision		
Diplopia	8 (5)	0
Vision Abnormal*	8 (5)	

	Table 4				
Ad	verse Hematologic Effects (Grade 3 to 4) in the				
Anaplastic Astrocytoma Trial in Adults					
TEMODAR ^a					
Hemoglobin	7/158 (4%)				
Lymphopenia	83/152 (55%)				
Neutrophils	20/142 (14%)				
Platelets	29/156 (19%)				
WBC	18/158 (11%)				

356 ^aChange from Grade 0 to 2 at baseline to Grade 3 or 4 during treatment.

*Blurred vision, visual deficit, vision changes, vision troubles.

357

In addition, the following spontaneous adverse experiences have been reported during the marketing surveillance of TEMODAR Capsules: allergic reactions, including rare cases of anaphylaxis. Rare cases of erythema multiforme have been reported which resolved after discontinuation of TEMODAR and, in some cases, recurred upon rechallenge. Rare cases of opportunistic infections including *Pneumocystis carinii* pneumonia (PCP) have also been reported.

364 OVERDOSAGE

Doses of 500, 750, 1,000, and 1,250 mg/m² (total dose per cycle over 5 days) have 365 been evaluated clinically in patients. Dose-limiting toxicity was hematologic and was 366 367 reported with any dose but is expected to be more severe at higher doses. An 368 overdose of 2,000 mg per day for 5 days was taken by one patient and the adverse 369 events reported were pancytopenia, pyrexia, multi-organ failure and death. There 370 are reports of patients who have taken more than 5 days of treatment (up to 64 371 days) with adverse events reported including bone marrow suppression, which in 372 some cases was severe and prolonged, and infections and resulted in death. In the



event of an overdose, hematologic evaluation is needed. Supportive measuresshould be provided as necessary.

375

376 DOSAGE AND ADMINISTRATION

Dosage of TEMODAR Capsules must be adjusted according to nadir neutrophil and platelet counts in the previous cycle and the neutrophil and platelet counts at the time of initiating the next cycle. For TEMODAR dosage calculations based on body surface area (BSA) see **Table 9**. For suggested capsule combinations on a daily dose see **Table 10**.

382

Patients with newly diagnosed high grade glioma:

384 Concomitant Phase

TEMODAR is administered orally at 75 mg/m² daily for 42 days concomitant with 385 386 focal radiotherapy (60Gy administered in 30 fractions) followed by maintenance 387 TEMODAR for 6 cycles. Focal RT includes the tumor bed or resection site with a 2-3 388 cm margin. No dose reductions are recommended during the concomitant phase; 389 however, dose interruptions or discontinuation may occur based on toxicity. The 390 TEMODAR dose should be continued throughout the 42 day concomitant period up to 49 days if all of the following conditions are met: absolute neutrophil count \ge 1.5 x 391 10^9 /L platelet count $\ge 100 \times 10^9$ /L common toxicity criteria (CTC) non-392 393 hematological toxicity ≤Grade 1 (except for alopecia, nausea and vomiting). During 394 treatment a complete blood count should be obtained weekly. Temozolomide dosing 395 should be interrupted or discontinued during concomitant phase according to the 396 hematological and non-hematological toxicity criteria as noted in **Table 5.** PCP 397 prophylaxis is required during the concomitant administration of Temodar and 398 radiotherapy and should be continued in patients who develop lymphocytopenia until 399 recovery from lymphocytopenia (CTC grade \leq 1).



400 Table 5 Temozolomide Dosing Interruption or Discontinuation During 401 Concomitant Radiotherapy and Temozolomide¹⁸ 402

Toxicity	TMZ Interruption ^a	TMZ Discontinuation	
Absolute Neutrophil Count	≥0.5 and <1.5 x 10 ⁹ /L	<0.5 x 10 ⁹ /L	
Platelet Count	≥10 and <100 x 10 ⁹ /L	<10 x 10 ⁹ /L	
CTC Non-hematological			
Toxicity			
(except for alopecia, nausea,			
vomiting)	CTC Grade 2	CTC Grade 3 or 4	

a: Treatment with concomitant TMZ could be continued when all of the following conditions were met: absolute neutrophil count ≥1.5 x 10⁹/L; platelet count ≥100 x 10⁹/L; CTC non-hematological toxicity ≤Grade 1 (except for alopecia, nausea, vomiting).

TMZ = temozolomide; CTC = Common Toxicity Criteria.

403

404 Maintenance Phase Cycle 1:

Four weeks after completing the TEMODAR + RT phase, TEMODAR is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m² once daily for 5 days followed by 23 days without treatment.

409

410 Cycles 2-6:

411 At the start of Cycle 2, the dose is escalated to 200 mg/m², if the CTC non-412 hematologic toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and 413 vomiting), absolute neutrophil count (ANC) is $\geq 1.5 \times 10^9$ /L, and the platelet count is 414 $\geq 100 \times 10^9$ /L. The dose remains at 200 mg/m² per day for the first 5 days of each 415 subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, 416 escalation should not be done in subsequent cycles.

417

418 **Dose reduction or discontinuation during maintenance:**

419 Dose reductions during the maintenance phase should be applied according to 420 tables **6** and **7**.

421 During treatment a complete blood count should be obtained on day 22 (21 days 422 after the first dose of Temodar) or within 48 hours of that day, and weekly until the ANC is above 1.5 x 10^{9} /L (1,500/µL) and the platelet count exceeds 100 x 10^{9} /L 423 424 (100,000/µL). The next cycle of TEMODAR should not be started until the ANC and 425 platelet count exceed these levels. Dose reductions during the next cycle should be 426 based on the lowest blood counts and worst non-hematologic toxicity during the 427 previous cycle. Dose reductions or discontinuations during the maintenance phase 428 should be applied according to tables 6 and 7.

- 429
- 430
- 431



432 Table 6 Temozolomide Dose Levels for Maintenance Treatment

433

Dose Level	Dose (mg/m²/day)	Remarks
–1	100	Reduction for prior toxicity
0	150	Dose during Cycle 1
1	200	Dose during Cycles 2-6 in absence of toxicity

434

Table 7 Temozolomide Dose Reduction or Discontinuation During Maintenance
 Treatment

437

Toxicity	Reduce TMZ by 1 Dose Level ^a	Discontinue TMZ
Absolute Neutrophil Count	<1.0 x 10 ⁹ /L	See footnote b
Platelet Count	<50 x 10 ⁹ /L	See footnote b
CTC Non-hematological Toxicity		
(except for alopecia, nausea,		
vomiting)	CTC Grade 3	CTC Grade 4 ^b

a: TMZ dose levels are listed in 6.

b: TMZ is to be discontinued if dose reduction to <100 mg/m² is required or if the same Grade 3 non-hematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.
 TMZ = temozolomide; CTC = Common Toxicity Criteria.

438

439

440 **Patients with refractory anaplastic astrocytoma**

441 For adults the initial dose is 150 mg/m² orally once daily for 5 consecutive days per 28-day treatment cycle. For adult patients, if both the nadir and day of dosing (Day 442 29, Day 1 of next cycle) ANC are \geq 1.5 x 10⁹/L (1,500/µL) and both the nadir and Day 443 29, Day 1 of next cycle platelet counts are $>100 \times 10^9$ /L (100,000/µL), the 444 TEMODAR dose may be increased to 200 mg/m²/day for 5 consecutive days per 28-445 446 day treatment cycle. During treatment, a complete blood count should be obtained 447 on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly 448 until the ANC is above 1.5 x 10^{9} /L (1,500/µL) and the platelet count exceeds 100 x 449 10⁹/L (100,000/µL). The next cycle of TEMODAR should not be started until the ANC 450 and platelet count exceed these levels. If the ANC falls to $<1.0 \times 10^{9}/L$ (1,000/µL) or the platelet count is $<50 \times 10^9$ /L (50.000/µL) during any cycle, the next cycle should 451 be reduced by 50 mg/m², but not below 100 mg/m², the lowest recommended dose 452 (see **Table 8**). TEMODAR therapy can be continued until disease progression. In 453 454 the clinical trial, treatment could be continued for a maximum of 2 years; but the 455 optimum duration of therapy is not known.



PAGE 16






		Table 10			
	Suggested Capsule Combinations Based on Daily Dose in Adults				
	nber of Daily	Capsules by Stre	ength (mg)		
Total Daily Dose (mg)	250	100	20	5	
75	0	0	3	3	
82.5	0	0	4	0	
90	0	0	4	2	
97.5	0	1	0	0	
105	0	1	0	1	
112.5	0	1	0	2	
120	0	1	1	0	
127.5	0	1	1	1	
135	0	1	1	3	
142.5	0	1	2	0	
150	0	1	2	2	
157.5	0	1	3	0	
165	0	1	3	1	
172.5	0	1	3	2	
180	0	1	4	0	
187.5	0	1	4	1	
195	0	1	4	3	
200	0	2	0	0	
210	0	2	0	2	
220	0	2	1	0	
225	0	2	1	1	
240	0	2	2	0	



	Tabl	e 10 continued			
Suggested Cap	Suggested Capsule Combinations Based on Daily Dose in Adults				
Nun	nber of Daily	Capsules by Stre	ength (mg)		
Total Daily Dose (mg)	250	100	20	5	
255	1	0	0	1	
260	1	0	0	2	
270	1	0	1	0	
280	1	0	1	2	
285	1	0	1	3	
300	0	3	0	0	
315	0	3	0	3	
320	0	3	1	0	
330	1	0	4	0	
340	0	3	2	0	
345	0	3	2	1	
360	0	3	3	0	
375	1	1	1	1	
380	1	1	1	2	
400	0	4	0	0	
420	0	4	1	0	
440	0	4	2	0	
460	1	2	0	2	
480	1	2	1	2	
500	2	0	0	0	

487

488

489 In clinical trials, TEMODAR was administered under both fasting and non-fasting 490 conditions: however. absorption is affected by food (see **CLINICAL** PHARMACOLOGY) and consistency of administration with respect to food is 491 492 recommended. There are no dietary restrictions with TEMODAR. To reduce nausea 493 and vomiting, TEMODAR should be taken on an empty stomach. Bedtime 494 administration may be advised. Antiemetic therapy may be administered prior to 495 and/or following administration of TEMODAR Capsules.

- 496 TEMODAR (temozolomide) Capsules should not be opened or chewed. They should497 be swallowed whole with a glass of water.
- 498

Handling and Disposal: TEMODAR causes the rapid appearance of malignant tumors in rats. Capsules should not be opened. If capsules are accidentally opened or damaged, rigorous precautions should be taken with the capsule contents to avoid inhalation or contact with the skin or mucous membranes. Procedures for proper handling and disposal of anticancer drugs should be considered¹⁻⁷. Several guidelines on this subject have been published. There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

506

507 HOW SUPPLIED

- 508 TEMODAR (temozolomide) Capsules are supplied in amber glass bottles with child 509 resistant polypropylene caps containing the following capsule strengths:
- 510 TEMODAR (temozolomide) Capsules 5 mg: 5 and 20 capsule bottles.
- 511 5 count NDC 0085-1248-01
- 512 20 count NDC 0085-1248-02



- 513 TEMODAR (temozolomide) Capsules 20 mg: 5 and 20 capsule bottles.
- 514 5 count NDC 0085-1244-01
- 515 20 count NDC 0085-1244-02
- 516 TEMODAR (temozolomide) Capsules 100 mg: 5 and 20 capsule bottles.
- 517 5 count NDC 0085-1259-01
- 518 20 count NDC 0085-1259-02
- 519 TEMODAR (temozolomide) Capsules 250 mg: 5 and 20 capsule bottles.
- 520 5 count NDC 0085-1252-01
- 521 20 count NDC 0085-1252-02
- 522

523 Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F).

- 524 [See USP Controlled Room Temperature]
- 525 526 **REFERENCES**

527 1. Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs, NIH
528 Publication No. 83-2621. For sale by the Superintendent of Documents, U.S.
529 Government Printing Office, Washington, DC 20402.

- 530 2. AMA Council Report, Guidelines for Handling Parenteral Antineoplastics. *JAM*A.
 531 1985; 2.53(11):1590-1592.
- 3. National Study Commission on Cytotoxic Exposure Recommendations for
 Handling Cytotoxic Agents. Available from Louis P. Jeffrey, ScD., Chairman,
 National Study Commission on Cytotoxic Exposure, Massachusetts College of
 Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston,
 Massachusetts 02115.
- 4. Clinical Oncological Society of Australia, Guidelines and Recommendations for
 Safe Handling of Antineoplastic Agents. *Med J Australia*. 1983; 1:426-428.
- 539 5. Jones RB, et al. Safe Handling Of Chemotherapeutic Agents: A Report from the 540 Mount Sinai Medical Center. CA - *A Cancer Journal for Clinicians*. 1983 ;(541 Sept/Oct):258-263.
- 6. American Society of Hospital Pharmacists Technical Assistance Bulletin on
 Handling Cytotoxic and Hazardous Drugs. *Am J Hosp Phar*m. 1990; 47:1033-1049.
- 544 7. Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice 545 Guidelines), *Am J Health-Syst Phar*m. 1996;53:1669-1685.

Schering Corporation

Kenilworth, NJ 07033 USA

- 546
- 547
- 548
- 549
- 550
- 551
- 552 Rev 3/05


- B-XXXXXXXX
- 553 Copyright © 2005, Schering Corporation. All rights reserved.
- 554



1	PAGE 1
1 2	PHARMACIST:
3 4	Tear at perforation and give to patient.
5 6 7 8	Temodar[®] [temozolomide] Capsules
9 10 11	PHARMACIST INFORMATION SHEET
12 13 14 15	IMPORTANT DISPENSING INFORMATION
16 17 18 19 20 21	IMPORTANT DISPENSING INFORMATION For every patient, TEMODAR must be dispensed in a separate vial or in its original glass bottle making sure each container lists the strength per capsule and that patients take the appropriate number of capsules from each bottle or vial. Please see the dispensing instructions below for more information.
22 23 24 25	What is TEMODAR? TEMODAR [®] (temozolomide) is an oral alkylating agent for the treatment of newly diagnosed glioblastoma multiforme and refractory anaplastic astrocytoma.
26 27 28 29 30 31 32 33 34 35	How is TEMODAR dosed? The daily dose of TEMODAR Capsules for a given patient is calculated by the physician, based on the patient's body surface area (BSA). The resulting dose is then rounded off to the nearest 5 mg. An example of the dosing may be as follows: the initial daily dose of TEMODAR in milligrams is the BSA multiplied by mg/m ² /day, (a patient with a BSA of 1.84 is 1.84 x 150 = 276, or 275 mg/day). The dose for subsequent cycles may be adjusted according to nadir neutrophil and platelet counts in the previous cycle and at the time of initiating the next cycle.
36 37 38 39 40	How might the dose of TEMODAR be modified for Refractory Anaplastic Astrocytoma? Dosage of TEMODAR must be adjusted according to nadir neutrophil and platelet counts in the previous cycle and neutrophil and platelet counts at the time of initiating the next cycle. The initial dose is 150 mg/m ² orally once daily for 5



41 consecutive days per 28-day treatment cycle. If both the nadir and day of dosing (Day 29, Day 1 of next cycle) absolute neutrophil counts (ANC) are $\geq 1.5 \times 10^9/L$ 42 43 (1,500/µL) and both the nadir and Day 29, Day 1 of next cycle platelet counts are \geq 100 x 10⁹/L (100.000/µL), the TEMODAR dose may be increased to 200 mg/m²/ 44 day for 5 consecutive days per 28-day treatment cycle. During treatment, a complete 45 blood count should be obtained on Day 22 (21 days after the first dose) or within 48 46 hours of that day, and weekly until the ANC is above 1.5×10^9 /L (1,500/µL) and the 47 platelet count exceeds 100 x 10⁹/L (100,000/µL). The next cycle of TEMODAR 48 49 should not be started until the ANC and platelet count exceed these levels. If the ANC falls to <1.0 x 10⁹/L (1,000/ μ L) or the platelet count is <50 x 10⁹/L (50,000/ μ L) 50 during any cycle, the next cycle should be reduced by 50 mg/m², but not below 100 51 52 mg/m^2 , the lowest recommended dose (see **Table 1** below).





77 78 What is the TEMODAR® (temozolomide) Capsules treatment regimen? TEMODAR is given for 5 consecutive days on a 28-day cycle. Patients should 79 continue taking TEMODAR until their physician determines that their disease has 80 81 progressed, up to 2 years, or until unacceptable side effects or toxicities occur. 82 Physicians may alter the treatment regimen for a given patient. 83 84 85 Newly Diagnosed Concomitant Phase Treatment Schedule TEMODAR is administered orally at 75 mg/m² daily for 42 days concomitant with 86 87 focal radiotherapy (60Gy administered in 30 fractions), followed by maintenance TEMODAR for 6 cycles.No dose reductions are recommended, however, dose 88 89 interruptions may occur based on patient tolerance. The TEMODAR dose can be 90 continued throughout the 42 day concomitant period up to 49 days if all of the following conditions are met: absolute neutrophil count \geq 1.5 x 10⁹ /L platelet count \geq 91 100 x10⁹ /L common toxicity criteria (CTC) non-hematological toxicity ≤Grade 1 92 (except for alopecia, nausea and vomiting). During treatment a complete blood count 93 should be obtained weekly. Temozolomide dosing should be interrupted or 94 95 discontinued during concomitant phase according to the hematological and nonhematological toxicity criteria as noted in Table 2. PCP prophylaxis is required 96 97

97 during the concomitant administration of Temodar and radiotherapy and should be 98 continued in patients who develop lymphocytopenia until recovery from 99 lymphocytopenia (CTC grade \leq 1).

100 101

102

103

 Table 2 Temozolomide Dosing Interruption or Discontinuation During Concomitant Radiotherapy and Temozolomide

Toxicity	TMZ Interruption ^a	TMZ Discontinuation
Absolute Neutrophil Count	≥0.5 and <1.5 x 10 ⁹ /L	<0.5 x 10 ⁹ /L
Platelet Count	≥10 and <100 x 10 ⁹ /L	<10 x 10 ⁹ /L
CTC Non-hematological		
Toxicity		
(except for alopecia, nausea,		
vomiting)	CTC Grade 2	CTC Grade 3 or 4

a: Treatment with concomitant TMZ could be continued when all of the following conditions were met: absolute neutrophil count ≥1.5 x 10⁹/L; platelet count ≥100 x 10⁹/L; CTC non-hematological toxicity ≤Grade 1 (except for alopecia, nausea, vomiting).

TMZ = temozolomide; CTC = Common Toxicity Criteria.

104

105 Maintenance Phase Treatment Schedule



106 Four weeks after completing the TEMODAR + RT phase, TEMODAR is 107 administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m² once daily for 5 days followed by 23 days without 108 treatment. At the start of Cycle 2, the dose is escalated to 200 mg/m², if the CTC 109 110 non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is $\geq 1.5 \times 10^{9}$ /L, and the platelet count is 111 112 \geq 100 x 10⁹/L. If the dose was not escalated at Cycle 2, escalation should not be 113 done in subsequent cycles. The dose remains at 200 mg/m² per day for the first 5 114 days of each subsequent cycle except if toxicity occurs.

115 During treatment a complete blood count should be obtained on Day 22 (21 days 116 after the first dose) or within 48 hours of that day, and weekly until the ANC is above 1.5×10^{9} /L (1.500/µL) and the platelet count exceeds 100 x 10⁹/L (100.000/µL). The 117 next cycle of TEMODAR should not be started until the ANC and platelet count 118 119 exceed these levels. Dose reductions during the next cycle should be based on the 120 lowest blood counts and worst non-hematologic toxicity during the previous cycle. 121 Dose reductions or discontinuations during the maintenance phase should be 122 applied according to tables 3 and 4.

- 123
- 124
- 125 126

 Table 3
 Temozolomide Dose Levels for Maintenance Treatment

Dose Level	Dose (mg/m²/day)	Remarks	
-1	100	Reduction for prior toxicity	
0	150	Dose during Cycle 1	
1	200	Dose during Cycles 2-6 in absence of toxicity	

127 128

 Table 4
 Temozolomide Dose Reduction or Discontinuation During Maintenance Treatment

Toxicity	Reduce TMZ by 1 Dose Level ^a	Discontinue TMZ
Absolute Neutrophil Count	<1.0 x 10 ⁹ /L	See footnote b
Platelet Count	<50 x 10 ⁹ /L	See footnote b
CTC Non-hematological Toxicity		
(except for alopecia, nausea,		
vomiting)	CTC Grade 3	CTC Grade 4 ^b

a: TMZ dose levels are listed in Table 3

b: TMZ is to be discontinued if dose reduction to <100 mg/m² is required or if the same Grade 3 non-hematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.
 TMZ = temozolomide; CTC = Common Toxicity Criteria.

129

130 How is TEMODAR taken?



PAGE 5

131 Patients should take each day's dose with a full glass of water at the same time 132 each day. Taking the medication on an empty stomach or at bedtime may help ease 133 nausea. If patients are also taking antinausea or other medications to relieve the 134 side effects associated with TEMODAR, they should be advised to take these 135 medications 30 minutes before they take TEMODAR. Temozolomide causes the 136 rapid appearance of malignant tumors in rats. Patients **SHOULD NOT** open or split 137 the capsules. If capsules are accidentally opened or damaged, rigorous precautions 138 should be taken with the capsule contents to avoid inhalation or contact with the skin 139 or mucous membranes. The medication should be kept away from children and 140 pets. The TEMODAR capsules should be swallowed whole and **NEVER CHEWED**.

141

142 What should the patient avoid during treatment with TEMODAR?

143 There are no dietary restrictions for patients taking TEMODAR. TEMODAR may 144 affect testicular function, so male patients should exercise adequate birth control 145 measures. TEMODAR may cause birth defects. Female patients should avoid 146 becoming pregnant while receiving this drug. Women who are nursing prior to 147 receiving TEMODAR should discontinue nursing. It is not known whether TEMODAR 148 is excreted into breast milk.

149 150

151 What are the side effects of TEMODAR?

152 Nausea and vomiting are the most common side effects associated with TEMODAR. 153 Noncumulative myelosuppression is the dose-limiting toxicity. Patients should be 154 evaluated periodically by their physician to monitor blood counts.

155

158

156 Other commonly reported side effects reported by patients taking TEMODAR 157 are fatigue, constipation, and headache.

159 How is **TEMODAR** supplied?

160 TEMODAR capsules are available in 250 mg, 100 mg, 20 mg, and 5 mg strengths. 161 The capsules are white with color-coded printing according to strength.

162

163 **TEMODAR Capsule Strength**

- Color 164 Green Imprint 5 mg 165 **Brown Imprint** 20 mg 166 100 mg Blue Imprint 167 Black Imprint 250 ma
- 168

169 All capsule strengths are available in 5-count and 20-count packages. 170

171 How is TEMODAR dispensed?

172 Each strength of TEMODAR must be dispensed in a separate vial or in its original 173 glass bottle (one strength per one container). Follow the instructions below:



PAGE 6

174 Based on the dose prescribed, determine the number of each strength of TEMODAR 175 capsules needed for the full 5 day cycle as prescribed by the physician. For 176 example, 275 mg/day for 5 days would be dispensed as five 250-mg capsules, five 177 20-mg capsules and five 5-mg capsules. Label each container with the appropriate 178 number of capsules to be taken each day. Dispense to the patient, making sure 179 each container lists the strength (mg) per capsule and that he or she understands to 180 take the appropriate number of capsules of TEMODAR from each bottle or vial to 181 equal the total daily dose prescribed by the physician.

183 How can TEMODAR be ordered?

184 TEMODAR can be ordered from your wholesaler. Remember to order enough
 185 TEMODAR for a full five-day cycle. For example, a five-day course of 275 mg/day
 186 would require the following to be ordered:

187 1 5-count package of 250-mg capsules

188 1 5-count package of 20-mg capsules

189 1 5-count package of 5-mg capsules

190

182

190			
191	TEMODAR Product	NDC Number	
192	250-mg capsules (5 count)	0085-1252-01	
193	250-mg capsules (20 count)	0085-1252-02	
194	100-mg capsules (5 count)	0085-1259-01	
195	100-mg capsules (20 count)	0085-1259-02	
196	20-mg capsules (5 count)	0085-1244-01	
197	20-mg capsules (20 count)	0085-1244-02	
198	5-mg capsules (5 count)	0085-1248-01	
199	5-mg capsules (20 count)	0085-1248-02	
200			

201 Copyright © 2005, Schering Corporation, Kenilworth, NJ 07033. All rights reserved.

202 22571613 Rev. <u>3/05</u>



Temodar® 1 2 [temozolomide] 3 Capsules 4 5 Patient Information Sheet 6 **IMPORTANT INFORMATION** 7 FOR THE PATIENT 8 Patient Package Insert **TEMODAR[®]** (temozolomide) Capsules

9 **TE**I 10

0

11 What is TEMODAR?

TEMODAR (temozolomide) is used to treat certain cancerous tumors in the brain of adult patients for whom this tumor has recurred. Your doctor has prescribed TEMODAR (temozolomide) as part of your cancer treatment. TEMODAR is a drug you take by mouth that interferes with cell growth, especially in cells that are growing rapidly, such as cancerous cells. TEMODAR has been shown to help slow the growth of certain cancerous tumors. When given to patients with brain cancer, TEMODAR has been shown to reduce the size of the tumor in some patients.

19

20 Who should not take TEMODAR?

You should not take TEMODAR Capsules if you have had an allergic reaction to DTIC-Dome (dacarbazine), a different treatment for cancer. If you have had an allergic reaction before to drugs such as DTIC-Dome, be sure to tell your doctor before taking TEMODAR. If you are allergic to drugs similar to TEMODAR,

25 you may also have an allergic reaction to TEMODAR.

26

27 How should I take TEMODAR?

28 Take each day's dose of capsules at one time, with a full glass of water. **DO NOT** 29 open or split the capsules. If the capsules are accidentally opened or damaged, you 30 should be extremely careful to avoid inhaling the powder in the capsules or getting it 31 on your skin or mucous membranes (eq, in nose or mouth). Flush the area with 32 water if contact occurs. The medication should be kept away from children and pets. 33 They should be swallowed whole and **NEVER CHEWED**. If capsules are vomited 34 do not take a second dose. New capsules should not be taken until the next 35 planned dose. The medicine is used best by your body if you take it at the same 36 time every day in relation to a meal. To reduce nausea, try to take TEMODAR on an 37 empty stomach or at bedtime. Your doctor may also have prescribed antinausea or 38 other medications to relieve the side effects associated with TEMODAR. Antinausea 39 medications should be taken as directed by your doctor. It is important that you 40 continue to see your doctor regularly to check your progress. Your doctor can 41 uncover side effects of treatment that you might not notice.



Because TEMODAR (temozolomide) Capsules is a drug you take by mouth, you can
take it at home. There are two different dosing schedules for taking TEMODAR.

45 Be sure you follow the one that your doctor has prescribed for you. One schedule 46 you may be prescribed is ,TEMODAR for 42 days (up to 49 days) with radiotherapy...

Another schedule should be taken for 5 consecutive days only, then you must **STOP** taking TEMODAR for the next 23 days. This total period of 5 days on TEMODAR and 23 days off TEMODAR is called one treatment cycle. Your dose is based on your height and weight, and the number of treatment cycles will depend on how you respond to and tolerate this treatment.

52 TEMODAR comes in different strength capsules (shown on the outer label in mg). 53 Each strength has a different color band. Depending on the dose of TEMODAR that 54 your doctor prescribes, you may have to take several capsules on each dosing day 55 of a treatment cycle (Day 1 through Day 5, followed by 23 days with no capsules) or 56 the 42 days (up to 49 days) of consecutive treatment schedule with radiotherapy.

- Be sure you understand exactly how many capsules you need to take of each strength. Ask your doctor or pharmacist to write down the number of each strength (include color) that you need to take each dosing day.
 - Be sure you know exactly which days are your dosing days.
 - Be sure to review the dose with your health care provider each time you start a new cycle. Sometimes the dose or the mix of capsules you need to take will be different from the last cycle.
 - Once you take the medicine home, if you are confused or unsure about how to take your dose, contact your doctor or pharmacist immediately.
- 65 66

60

61

62

63

64

Your doctor may have prescribed a treatment regimen that is different from the one 67 68 discussed in this information sheet. If so, make sure you follow the specific 69 instructions given to you by your doctor. You should talk to your doctor about what to 70 do if you miss a day. If you take more than the prescribed amount of medicine, 71 contact your doctor right away. It is important that you understand your dosage 72 regimen, it is also important that you do not take more than the amount of 73 TEMODAR prescribed for you. Overdoses can lead to serious outcomes including 74 severe low blood counts and possible death.

75

80

76 How is TEMODAR supplied?

TEMODAR® (temozolomide) Capsules are white with color-coded printing according
to strength, each a different size. The capsules are available in four different
strengths.

81	TEMODAR Capsule Strength	<u>Color</u>
82	5mg	Green Imprint
83	20mg	Brown Imprint
84	100mg	Blue Imprint
85	250mg	Black Imprint
86		



87 What should I avoid while taking TEMODAR?

- There are no limitations on what you may eat or drink while taking TEMODAR.However, to ease nausea, try to take TEMODAR on an empty stomach.
- 90
- 91 TEMODAR may cause birth defects. Therefore, male or female patients who take

92 TEMODAR should use effective birth control. Female patients should avoid 93 becoming pregnant while receiving this drug. You should not breast-feed an infant 94 while taking TEMODAR. It is not known whether TEMODAR passes into breast 95 milk. Because many drugs do pass into breast milk, there is the possibility of serious 96 harm to nursing infants.

97

98 What are the possible or reasonably likely side effects of TEMODAR?

Nausea and vomiting are the most common side effects associated with TEMODAR.
Your doctor can prescribe medicines that may help reduce some of these. Other
common side effects include headache, feeling tired, and constipation.

102

103 TEMODAR also can reduce the number of certain types of blood cells, which can 104 have serious effects. White blood cells are needed to fight infections. Lowering of 105 white blood cells could result in a serious infection with a potential outcome of death. 106 Platelets are needed in the normal course of blood clotting. Lowering of platelets 107 does not allow your blood to clot normally, which can result in bleeding episodes. 108 Therefore, it is important that your doctor check your blood periodically while you are taking TEMODAR to see if these side effects are occurring. Patients age 70 or older, 109 110 women, and patients who have had chemotherapy or radiation therapy may be more 111 likely to have their blood cells affected.

112

113 There are other side effects associated with TEMODAR. They are included in a 114 longer, more technical information leaflet written for health care providers that you 115 can get from your doctor or pharmacist.

116

117 General information about the use of prescription drug products.

118 Medicines are sometimes prescribed for purposes other than those listed in a

Patient Package Insert. You should contact your health care professional regarding any concerns you may have about using TEMODAR. TEMODAR should not be used for a condition for which it was not prescribed, and it should not be given to other persons.

- 123
- 124 Copyright ©2004, Schering Corporation,
- 125 Kenilworth, NJ 07033. All rights reserved.
- 126 22571613 Rev. 08/04
- 127

